2020 MIPS IA_PSPA_6: Consultation of the Prescription Drug Monitoring program

Activity ID


Activity Weighting


Subcategory Name

Patient Safety and Practice Assessment

Activity Description

Clinicians would attest to reviewing the patients' history of controlled substance prescription using state prescription drug monitoring program (PDMP) data prior to the issuance of a Controlled Substance Schedule II (CSII) opioid prescription lasting longer than 3 days. For the transition year, clinicians would attest to 60 percent review of applicable patient's history. For the Quality Payment Program Year 2 and future years, clinicians would attest to 75 percent review of applicable patient's history performance.


Provision of consulting with PDMP before issuance of a controlled substance schedule II opioid prescription that lasts longer than 3 days

Suggested Documentation

1) Number of Issuances of CSII Prescription - Total number of issuances of a CSII prescription that lasts longer than 3 days over the same time period as those consulted; and
2) Documentation of Consulting the  PDMP - Total number of patients for which there is evidence of consulting the PDMP prior to issuing an CSII prescription (e.g. copies of patient reports created, with the PHI masked).

Register with MDinteractive